株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

変形性関節症治療薬の世界市場 - 2024年までの予測:関節内補充薬・非ステロイド性抗炎症薬・鎮痛剤・コルチコステロイド

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 914242
出版日 ページ情報 英文 148 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
変形性関節症治療薬の世界市場 - 2024年までの予測:関節内補充薬・非ステロイド性抗炎症薬・鎮痛剤・コルチコステロイド Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024
出版日: 2019年10月15日 ページ情報: 英文 148 Pages
概要

世界の変形性関節症治療薬市場は、2019年の68億米ドルから2024年までに101億米ドルへ達すると予測され、予測期間中は8.1%のCAGR (年間複合成長率) が見込まれています。同産業の成長は、高齢者・肥満人口の増加およびそれに関連した変形性関節症の有病率の上昇です。一方、代替となる非薬物疼痛管理療法を利用できることは、主要な市場課題となっています。

当レポートでは、世界の変形性関節症治療薬市場について調査分析し、市場概要、産業動向、各セグメント別・地域別による市場の分析と予測、競合情勢、主要企業などについて、体系的な情報を提供しています。

914242_4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW_FIGURE 13

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 変形性関節症治療薬市場の概要
  • 欧州における変形性関節症治療薬市場のシェア:部位別
  • 変形性関節症治療薬市場の地域スナップショット

第5章 市場概要

  • イントロダクション
  • 市場のダイナミクス
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題

第6章 変形性関節症治療薬市場:部位別

  • イントロダクション
  • 変形性膝関節症
  • 変形性股関節症
  • 変形性手関節症
  • 変形性小関節症

第7章 変形性関節症治療薬市場:薬剤タイプ別

  • イントロダクション
  • 関節内補充薬
  • 非ステロイド性抗炎症薬
  • 鎮痛剤
  • コルチコステロイド

第8章 変形性関節症治療薬市場:投与経路別

  • イントロダクション
  • 経口経路
  • 非経口経路
  • 局所経路

第9章 変形性関節症治療薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • オンライン薬局
  • 小売り薬局

第10章 変形性関節症治療薬市場:購入パターン別

  • イントロダクション
  • 処方薬
  • OTC医薬品

第11章 変形性関節症治療薬市場:地域別

  • イントロダクション
  • 欧州
  • 北米
  • アジア太平洋
  • その他 (RoW)

第12章 競合情勢

  • 概要
  • 市場ランキング分析
  • 競合シナリオ
  • 競合リーダーシップマッピング

第13章 企業プロファイル

  • SANOFI
  • HORIZON THERAPEUTICS PLC
  • JOHNSON & JOHNSON
  • GLAXOSMITHKLINE PLC
  • BAYER AG
  • ABBOTT
  • PFIZER, INC.
  • ELI LILLY
  • ANIKA THERAPEUTICS, INC.
  • NOVARTIS
  • FERRING PHARMACEUTICALS
  • BIOVENTUS
  • ZIMMER BIOMET HOLDINGS, INC.
  • FIDIA FARMACEUTICI S.P.A.
  • FLEXION THERAPEUTICS, INC.

第14章 付録

図表

LIST OF TABLES

  • TABLE 1 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 40
  • TABLE 2 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 41
  • TABLE 3 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 42
  • TABLE 4 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 43
  • TABLE 5 SMALL-JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 44
  • TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 46
  • TABLE 7 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2017-2024 (USD MILLION) 47
  • TABLE 8 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 47
  • TABLE 9 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2017-2024 (USD MILLION) 48
  • TABLE 10 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2017-2024 (USD MILLION) 48
  • TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2017-2024 (USD MILLION) 49
  • TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION, 2017-2024 (USD MILLION) 49
  • TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2017-2024 (USD MILLION) 50
  • TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER MOLECULES, BY REGION, 2017-2024 (USD MILLION) 50
  • TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 51
  • TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2017-2024 (USD MILLION) 51
  • TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2017-2024 (USD MILLION) 52
  • TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2017-2024 (USD MILLION) 52
  • TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2017-2024 (USD MILLION) 53
  • TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 55
  • TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION) 56
  • TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PARENTERAL ROUTE OF ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION) 56
  • TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION) 57
  • TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 59
  • TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2017-2024 (USD MILLION) 59
  • TABLE 26 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2017-2024 (USD MILLION) 60
  • TABLE 27 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2017-2024 (USD MILLION) 61
  • TABLE 28 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 63
  • TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2017-2024 (USD MILLION) 63
  • TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2017-2024 (USD MILLION) 64
  • TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 66
  • TABLE 32 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 68
  • TABLE 33 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 68
  • TABLE 34 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 69
  • TABLE 35 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 69
  • TABLE 36 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 69
  • TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 70
  • TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 70
  • TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 70
  • TABLE 40 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 71
  • TABLE 41 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 71
  • TABLE 42 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 72
  • TABLE 43 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 72
  • TABLE 44 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 72
  • TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 73
  • TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 73
  • TABLE 47 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 74
  • TABLE 48 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 74
  • TABLE 49 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 74
  • TABLE 50 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 75
  • TABLE 51 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 75
  • TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 75
  • TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 76
  • TABLE 54 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 76
  • TABLE 55 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 77
  • TABLE 56 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 77
  • TABLE 57 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 77
  • TABLE 58 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 78
  • TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 78
  • TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 78
  • TABLE 61 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 79
  • TABLE 62 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 79
  • TABLE 63 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 80
  • TABLE 64 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 80
  • TABLE 65 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 80
  • TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 81
  • TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 81
  • TABLE 68 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 82
  • TABLE 69 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 82
  • TABLE 70 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 82
  • TABLE 71 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 83
  • TABLE 72 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 83
  • TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 83
  • TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 84
  • TABLE 75 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 84
  • TABLE 76 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 85
  • TABLE 77 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 85
  • TABLE 78 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 85
  • TABLE 79 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 86
  • TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 86
  • TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 86
  • TABLE 82 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 87
  • TABLE 83 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 87
  • TABLE 84 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 88
  • TABLE 85 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 88
  • TABLE 86 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 88
  • TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 89
  • TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 89
  • TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 89
  • TABLE 90 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 90
  • TABLE 91 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 91
  • TABLE 92 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 91
  • TABLE 93 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 91
  • TABLE 94 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 92
  • TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 92
  • TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 92
  • TABLE 97 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 93
  • TABLE 98 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 94
  • TABLE 99 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 94
  • TABLE 100 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 94
  • TABLE 101 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 95
  • TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 95
  • TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 95
  • TABLE 104 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 97
  • TABLE 105 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 97
  • TABLE 106 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 98
  • TABLE 107 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 98
  • TABLE 108 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 98
  • TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 99
  • TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 99
  • TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 99
  • TABLE 112 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 100
  • TABLE 113 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 100
  • TABLE 114 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 101
  • TABLE 115 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 101
  • TABLE 116 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 101
  • TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 102
  • TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 102
  • TABLE 119 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 103
  • TABLE 120 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 103
  • TABLE 121 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 103
  • TABLE 122 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 104
  • TABLE 123 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 104
  • TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 104
  • TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 105
  • TABLE 126 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 105
  • TABLE 127 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 106
  • TABLE 128 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 106
  • TABLE 129 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 107
  • TABLE 130 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 107
  • TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 107
  • TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 108
  • TABLE 133 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 108
  • TABLE 134 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 109
  • TABLE 135 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 109
  • TABLE 136 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 109
  • TABLE 137 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 110
  • TABLE 138 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 110
  • TABLE 139 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 110
  • TABLE 140 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017-2024 (USD MILLION) 111
  • TABLE 141 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017-2024 (USD MILLION) 112
  • TABLE 142 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017-2024 (USD MILLION) 112
  • TABLE 143 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017-2024 (USD MILLION) 112
  • TABLE 144 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 113
  • TABLE 145 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2024 (USD MILLION) 113
  • TABLE 146 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017-2024 (USD MILLION) 114

LIST OF FIGURES

  • FIGURE 1 OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION 18
  • FIGURE 2 RESEARCH DESIGN 20
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
  • FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH 23
  • FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH 24
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY 25
  • FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2019 VS. 2024 (USD BILLION) 27
  • FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2019 VS. 2024 (USD BILLION) 28
  • FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019 VS. 2024 (USD BILLION) 28
  • FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019 VS. 2024 (USD BILLION) 29
  • FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2019 VS. 2024 (USD BILLION) 29
  • FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD BILLION) 30
  • FIGURE 13 HIGH AND GROWING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET 31
  • FIGURE 14 KNEE OSTEOARTHRITIS THERAPEUTICS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2019 32
  • FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 33
  • FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 34
  • FIGURE 17 GERIATRIC POPULATION, BY REGION, 2017 VS. 2050 35
  • FIGURE 18 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT 67
  • FIGURE 19 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT 96
  • FIGURE 20 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET FROM JANUARY 2016 TO AUGUST 2019 115
  • FIGURE 21 TOP 5 COMPANIES IN THE OSTEOARTHRITIS THERAPEUTICS MARKET 115
  • FIGURE 22 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 119
  • FIGURE 23 SANOFI: COMPANY SNAPSHOT (2018) 120
  • FIGURE 24 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2018) 122
  • FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018) 123
  • FIGURE 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT 124
  • FIGURE 27 BAYER AG: COMPANY SNAPSHOT (2018) 126
  • FIGURE 28 ABBOTT: COMPANY SNAPSHOT (2018) 127
  • FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2018) 128
  • FIGURE 30 ELI LILLY: COMPANY SNAPSHOT (2018) 129  
  • FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2018) 131
  • FIGURE 32 NOVARTIS: COMPANY SNAPSHOT (2018) 133
  • FIGURE 33 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2018) 137
  • FIGURE 34 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2018) 139
目次
Product Code: PH 7393

"The osteoarthritis therapeutics market is projected to register a CAGR of 8.1% during the forecast period."

The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 8.1%. Growth in this industry is driven by the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. On the other hand, the availability of alternative non-drug pain management therapies is a major market challenge.

"Knee osteoarthritis segment to witness the highest growth during the forecast period."

Based on anatomy, the osteoarthritis therapeutics market is segmented into knee, hip, hand, and small-joint. The knee osteoarthritis segment is projected to grow at the highest CAGR during the forecast period. A large number of patients suffering from knee osteoarthritis is the major factor supporting the growth of this segment.

"Viscosupplementation agents segment to register the highest growth in the osteoarthritis therapeutics market during the forecast period."

Based on drug type, the osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is sub-segmented into duloxetine and acetaminophen, while the NSAIDs segment is sub-segmented into naproxen, aspirin, diclofenac, ibuprofen, and other molecules. The viscosupplementation agents segment is projected to witness the highest growth in the osteoarthritis therapeutics market during the forecast period. The rising incidence of knee osteoarthritis is one of the major factors supporting the growth of this segment.

"Asia Pacific is estimated to register the highest CAGR during the forecast period."

In this report, the osteoarthritis therapeutics market is segmented into four major regional segments, namely, Europe, North America, Asia Pacific, and the Rest of the World (RoW). The market in Asia-Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is driven primarily by the rising incidence and prevalence of osteoarthritis, increasing geriatric and obese populations, and healthcare infrastructure improvements in several APAC countries.

Breakdown of Profiles of Primary Participants:

  • By Company Type: Tier 1: 20%, Tier 2: 45%, and Tier 3: 35%
  • By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
  • By Region: North America: 35%, Europe: 24%, Asia Pacific: 25%, and the Rest of the World: 16%

Key players in the osteoarthritis therapeutics market include: Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline Plc (UK), Bayer AG (Germany), Abbott (US), Pfizer (US), Eli Lilly (US), Anika Therapeutics (US), and Flexion Therapeutics (US).

Research Coverage:

The report analyzes the osteoarthritis therapeutics market by anatomy, drug type, route of administration, distribution channel, purchasing pattern, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the osteoarthritis therapeutics market
  • Product Development/Innovation: Detailed insights on the product approvals, R&D activities, and product launches in the osteoarthritis therapeutics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the osteoarthritis therapeutics market
  • Market Development: Detailed information about emerging markets. The report analyzes the market for various osteoarthritis therapeutics across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the osteoarthritis therapeutics market

TABLE OF CONTENTS

1 INTRODUCTION 17

  • 1.1 OBJECTIVES OF THE STUDY 17
  • 1.2 MARKET DEFINITION 17
  • 1.3 MARKET SCOPE 18
    • 1.3.1 MARKETS COVERED 18
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 19
  • 1.4 CURRENCY 19
  • 1.5 LIMITATIONS 19
  • 1.6 STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20

  • 2.1 RESEARCH DATA 20
    • 2.1.1 SECONDARY DATA 21
      • 2.1.1.1 Key data from secondary sources 21
    • 2.1.2 PRIMARY DATA 21
      • 2.1.2.1 Key data from primary sources 22
  • 2.2 MARKET SIZE ESTIMATION 23
    • 2.2.1 BOTTOM-UP APPROACH 23
    • 2.2.2 TOP-DOWN APPROACH 24
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
  • 2.4 ASSUMPTIONS FOR THE STUDY 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 31

  • 4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW 31
  • 4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY ANATOMY (2018) 32
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET 33

5 MARKET OVERVIEW 34

  • 5.1 INTRODUCTION 34
  • 5.2 MARKET DYNAMICS 34
    • 5.2.1 DRIVERS 35
      • 5.2.1.1 Rapid growth in the geriatric and obese populations and the associated increase in the prevalence of osteoarthritis 35
      • 5.2.1.2 Increasing incidence of sports injuries 36
    • 5.2.2 RESTRAINTS 37
      • 5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment 37
    • 5.2.3 OPPORTUNITIES 37
      • 5.2.3.1 Emerging markets 37
      • 5.2.3.2 Strategic collaborations focused on new product development 37
    • 5.2.4 CHALLENGES 38
      • 5.2.4.1 Availability of alternative non-drug pain management therapies 38

6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY 39

  • 6.1 INTRODUCTION 40
  • 6.2 KNEE OSTEOARTHRITIS 40
    • 6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS 40
  • 6.3 HIP OSTEOARTHRITIS 41
    • 6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS 41
  • 6.4 HAND OSTEOARTHRITIS 42
    • 6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH 42
  • 6.5 SMALL-JOINT OSTEOARTHRITIS 43
    • 6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS 43

7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE 45

  • 7.1 INTRODUCTION 46
  • 7.2 VISCOSUPPLEMENTATION AGENTS 46
    • 7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2018 46
  • 7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 47
    • 7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE VARIOUS POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH CORTICOSTEROIDS 47
      • 7.3.1.1 Ibuprofen 48
      • 7.3.1.2 Diclofenac 49
      • 7.3.1.3 Aspirin 49
      • 7.3.1.4 Naproxen 50
      • 7.3.1.5 Other molecules 50
  • 7.4 ANALGESICS 51
    • 7.4.1 ACETAMINOPHEN 52
    • 7.4.2 DULOXETINE 52
  • 7.5 CORTICOSTEROIDS 53

8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 54

  • 8.1 INTRODUCTION 55
  • 8.2 ORAL ROUTE 55
  • 8.3 PARENTERAL ROUTE 56
  • 8.4 TOPICAL ROUTE 57

9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 58

  • 9.1 INTRODUCTION 59
  • 9.2 HOSPITAL PHARMACIES 59
  • 9.3 ONLINE PHARMACIES 60
  • 9.4 RETAIL PHARMACIES 61

10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN 62

  • 10.1 INTRODUCTION 63
  • 10.2 PRESCRIPTION DRUGS 63
    • 10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET 63
  • 10.3 OVER-THE-COUNTER DRUGS 64
    • 10.3.1 EASE OF PURCHASE AND ADMINISTRATION RESULTING IN A RISING DEMAND FOR OTC DRUGS 64

11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION 65

  • 11.1 INTRODUCTION 66
  • 11.2 EUROPE 67
    • 11.2.1 ITALY 71
    • 11.2.2 GERMANY 73
    • 11.2.3 SPAIN 76
    • 11.2.4 FRANCE 79
    • 11.2.5 UK 81
    • 11.2.6 REST OF EUROPE 84
  • 11.3 NORTH AMERICA 87
    • 11.3.1 US 90
    • 11.3.2 CANADA 93
  • 11.4 ASIA PACIFIC 96
    • 11.4.1 JAPAN 100
    • 11.4.2 CHINA 102
    • 11.4.3 INDIA 105
    • 11.4.4 REST OF ASIA PACIFIC 108
  • 11.5 REST OF THE WORLD 111

12 COMPETITIVE LANDSCAPE 115

  • 12.1 OVERVIEW 115
  • 12.2 MARKET RANKING ANALYSIS, 2018 115
  • 12.3 COMPETITIVE SCENARIO 116
    • 12.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016-2019 116
    • 12.3.2 COLLABORATIONS, 2016-2019 117
    • 12.3.3 EXPANSIONS, 2016-2019 117
    • 12.3.4 ACQUISITIONS, 2016-2019 117
    • 12.3.5 OTHER DEVELOPMENTS 118
  • 12.4 COMPETITIVE LEADERSHIP MAPPING 118
    • 12.4.1 VENDOR INCLUSION CRITERIA 118
    • 12.4.2 VISIONARY LEADERS 118
    • 12.4.3 INNOVATORS 118
    • 12.4.4 DYNAMIC DIFFERENTIATORS 118
    • 12.4.5 EMERGING COMPANIES 119

13 COMPANY PROFILES 120

(Business overview, Products offered, Recent developments, MNM view)*

  • 13.1 SANOFI 120
  • 13.2 HORIZON THERAPEUTICS PLC 122
  • 13.3 JOHNSON & JOHNSON 123
  • 13.4 GLAXOSMITHKLINE PLC 124
  • 13.5 BAYER AG 126
  • 13.6 ABBOTT 127
  • 13.7 PFIZER, INC. 128
  • 13.8 ELI LILLY 129
  • 13.9 ANIKA THERAPEUTICS, INC. 131
  • 13.10 NOVARTIS 133
  • 13.11 FERRING PHARMACEUTICALS 134
  • 13.12 BIOVENTUS 135
  • 13.13 ZIMMER BIOMET HOLDINGS, INC. 137
  • 13.14 FIDIA FARMACEUTICI S.P.A. 138
  • 13.15 FLEXION THERAPEUTICS, INC. 139

Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX 141

  • 14.1 DISCUSSION GUIDE 141
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 144
  • 14.3 AVAILABLE CUSTOMIZATIONS 146
  • 14.4 RELATED REPORTS 146
  • 14.5 AUTHOR DETAILS 147
Back to Top